BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 29855694)

  • 1. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
    Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
    Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cells as effectors of immune suppression in cancer.
    Pyzer AR; Cole L; Rosenblatt J; Avigan DE
    Int J Cancer; 2016 Nov; 139(9):1915-26. PubMed ID: 27299510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
    Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
    Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
    Hou A; Hou K; Huang Q; Lei Y; Chen W
    Front Immunol; 2020; 11():783. PubMed ID: 32508809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
    Cai J; Cui Y; Yang J; Wang S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunobiology of myeloid-derived suppressor cells in cancer.
    Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
    Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of myeloid-derived suppressor cells in hematologic malignancies.
    Gunes EG; Rosen ST; Querfeld C
    Curr Opin Oncol; 2020 Sep; 32(5):518-526. PubMed ID: 32675593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
    Ostrand-Rosenberg S; Fenselau C
    J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.
    Yang Y; Li C; Liu T; Dai X; Bazhin AV
    Front Immunol; 2020; 11():1371. PubMed ID: 32793192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
    Chen Z; Yuan R; Hu S; Yuan W; Sun Z
    Front Immunol; 2022; 13():817942. PubMed ID: 35154134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.
    Tobin RP; Davis D; Jordan KR; McCarter MD
    J Leukoc Biol; 2017 Aug; 102(2):381-391. PubMed ID: 28179538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
    Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
    Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
    Law AMK; Valdes-Mora F; Gallego-Ortega D
    Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
    Kramer ED; Abrams SI
    Front Immunol; 2020; 11():1963. PubMed ID: 32983128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.